News

Trequant, Inc., a wearable device startup, is launching a Kickstarter campaign to raise money to market and further develop its tremor quantifying device. The Trequant wearable is designed to appear and feel like a normal analog watch, but contains advanced sensors that monitor the extremity tremors common to movement disorders like Parkinson’s disease…

The U.S. Food and Drug Administration (FDA) has approved for the first time a drug to treat the hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). The drug, Nuplazid (pimavanserin), produced by Acadia Pharmaceuticals, had been designated a Breakthrough Therapy by the FDA in 2014. “Today’s approval of NUPLAZID represents a…

University of Texas Health Science Center researchers have identified physiologic changes in dopamine neurons in a key animal model of Parkinson’s known to display disease symptoms, the MitoPark mouse model. The dopamine changes in the mice, however, clearly came before any symptoms appeared — findings that may lead to earlier identification of  Parkinson’s in people,…

Acorda Therapeutics recently presented results from a Phase 2b study of its investigational drug CVT-301 in patients with Parkinson’s disease (PD) at the 68th Annual Meeting of the American Academy of Neurology in Vancouver, Canada. “Approximately 350,000 people with PD in the U.S. experience OFF periods, which can be very disruptive. There…